Overall, our data shows that plasma NfL is robustly elevated following HD symptom onset and, further, that plasma NfL may contribute essential prognostic value in premanifest HD with regard to the most appropriate time to initiate disease-modifying therapies. This evidence concerns the gene NEFL and Huntington disease.